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Sarcomas represent a heterogeneous group of cancers thought to originate from malignant transformation of mesenchymal cells.
Thereisincreasingevidencethatmany,ifnotall,sarcomascontainwithinthemtumor-initiating,or“cancerstem,”cellsresponsible
fortheinitiation,maintenance,andpotentiallyrelapseandmetastasisofthetumor.Varioustechniqueshavebeenadoptedinrecent
years to identify putative sarcoma stem cell populations. The goal of this paper is to summarize the criteria used to identify a stem
cell population, describe the more prominent markers and techniques used to isolate cancer stem cells in sarcomas, and review the
evidence for the existence of cancer stem cells in sarcomas.
1.Introduction
Sarcomas represent a heterogeneous group of cancers that
seem to originate from malignant transformation of mes-
enchymal cells. Whether they represent malignant transfor-
mation of mesenchymal stem cells or of diﬀerentiated cells
of mesenchymal origin has not been established. There is
increasing evidence that many, if not all, cancers constitute
a hierarchy of cells including so-called cancer stem cells
that are believed to be the progenitor cells from which the
tumor was spawned and that these cancer stem cells may
be responsible for relapses and metastases [1]. Cancer stem
cells appear to be resistant to chemotherapy, may remain
quiescent for extended periods, perhaps have an aﬃnity for
hypoxic environments, and may have a predisposition for
migration andmetastasis. Additionally, since the cancerstem
cell model suggests that these cells make up a very small
portion of the tumor bulk, the majority being their progeny,
the model also would oﬀer an explanation for relapses that
occur despite what would appear to be a total response to
initial therapeutic interventions.
An underlying matter is the origin of cancer stem cells.
The use of the term “cancer stem cells” is suggestive that
these are normal stem cells that have undergone malignant
transformation and thus have become cancerous. Though
this interpretation is understandable and this is a plausible
source of cancer stem cells, it is by no means established that
this is how cancer stem cells come to be. Alternatively, cancer
stem cells may derive from diﬀerentiated cells that, through
malignant transformation, acquire properties reminiscent of
stem cells. To avoid the ambiguity of the term “cancer stem
cell,” for the remainder of this review the terms tumor-
initiating cell (TIC) and sarcoma-initiating cell (SIC) will be
used.
TobetterstudySICsanddeveloptherapiestotargetthem,
they must ﬁrst be identiﬁed and isolated. Several techniques
foridentifyingandisolatingTIChavebeenusedwithvarying
success in other more common malignancies, and these
techniquesarebeingstudiedonthegamutofsarcomas.Most
of these techniques involve identifying a subpopulation of
cancercellsthathavepropertiestypicallyseenonlyinnormal
stem cells. We will describe the more prominent techniques
for TIC identiﬁcation and isolation being used in sarcomas
(Table 1) and discuss the evidence supporting the existence
of SICs.
2. Stem CellAssays
ThedeﬁnitionofaTICandthemeansbywhichtodetermine
that a population contains TICs remain points of contention2 Sarcoma
Table 1: Techniques used to isolate sarcoma-initiating cells.
Technique Description
Surface markers
(e.g., CD133)
Cells are incubated with ﬂuorescent
antibodies to speciﬁc surface markers.
Flow-cytometry is used to isolate cells
expressing surface marker
Aldehyde
Dehydrogenase
(ALDH)
Cells are incubated with reagent that is
a c t i v a t e dt oﬂ u o r e s c e n ts t a t eb yA L D H .
Flow-cytometry is used to isolate the cells
with the most ALDH activity
Side
population analysis
(dye exclusion)
Cells are incubated with a ﬂuorescent dye
such as Hoechst 33342. Flow-cytometry
is used to select the population that
excludes the dye, referred to as the “side
population,” because of its location on
the left-most portion of the ﬂowplot
[2]. The following are the most commonly used assays for
stem cell-like properties. They include functional tests of
the ability to behave like a TIC as well as descriptive assays
evaluating if cells have qualities expected in TICs.
2.1. Functional Assays
2.1.1. Clonogenic/Sphere-Forming Assay. TICs are believed to
have an increased ability to form colonies from a single cell
as compared to their progeny [3]. Colony-forming assays
are performed by preparing a single cell suspension and
plating the cells in soft agar. Colonies that grow from the
individual cells are typically stained with crystal violet and
counted and measured using a stereomicroscope. The ability
to form colonies in soft agar is presumed to be unique to
stem cells, but one may question if a malignant cell line able
to grow in vitro may not also be capable of growing in soft
agar. Another issue with this assay is whether the size of the
colonyisareﬂectionof“stemness”(typicallysmallercolonies
are excluded from the counts). The size of the colony may
simply be a measure of proliferation or quiescence and not
presence or absence of a TIC. Additionally, clonogenic assay
results can be inﬂuenced by technical considerations. The
agaristypicallyautoclavedandmixedwithmediacontaining
suﬃciently diluted cells when the temperature is low enough
to not kill the cells, but still warm enough to be poured into
wells.Propercelldilutioniscriticaltoensurethateachcolony
results from a single cell, and toxicity to cells from agar that
is too hot may also aﬀect results.
Sphere-formingassaysassesstheabilityofcellstogrowas
spheres in nonadherent conditions [4]. This is also thought
to be a unique property of TICs, but some cell lines appear
to display this ability ubiquitously. The same issues of cell
dilution apply to this assay, as cell clumps bear a striking
resemblance to spheres. Finally, what both of these assays
really measure is a cell’s ability to behave like a TIC when
removed from an in vivo niche, rather than truly detecting
TICs.
2.1.2. Tumorigenesis. The ability to grow serially trans-
plantable tumors in immunodeﬁcient mice is considered
by some to be the “gold standard” characteristic of TICs
[5]. Theoretically, a single TIC should be able to generate
a tumor; however, no studies have been able to purify a
population to that degree. What usually is reported is that
the putative TIC population is able to grow a tumor with
a smaller number of cells inoculated into a mouse than
the nonTIC population. There are, however, no set criteria
for what is considered a signiﬁcant diﬀerence between
tumorigenesis in the two populations, and there is no
consensus on what strain of mouse to test tumorigenesis.
2.1.3. Dye Eﬄux. ATP-binding cassette (ABC) transporter
eﬄux of DNA-binding dyes such as Hoechst 33342 or
Rhodamine 123 is also used as an indicator of stem cell
properties [6]. Exclusion of the dye is what identiﬁes “side
population” (SP) by ﬂow cytometry. The activity of the ABC
transporters can be blocked by the calcium-channel blocker
verapamil. One of the challenges of using SP as a measure of
TICs is that Hoechst dye, for example, may be toxic to cells
[7]. As such, cells that are identiﬁed by exclusion of this dye
will have a survival advantage over cells that are not able to
eﬄux the dye as readily. There is also evidence that TICs can
be found in the nonSP, suggesting that exclusion of Hoechst
33342 is not an essential quality of TICs [8, 9].
2.1.4. Chemoresistance. Somewhat related to drug eﬄux,
chemotherapy resistance is also considered a hallmark
of TICs [10]. Part of what makes the cancer stem cell
theory attractive is the idea that the TICs survive all
therapeutic interventions and then may cause relapse and
metastases [11]. Thus, dose response curves to standard
chemotherapeutic agents are performed on candidate TIC
populations and compared to the nonTIC population. It is
expected that the TICs will demonstrate relative resistance
to chemotherapy. One potential confounding factor is that
TICs may avoid the toxicity of chemotherapy by remaining
quiescent, since chemotherapy tends to be more toxic to
rapidly proliferating cells. If this is the case, a proliferation or
viabilityassaymayunderestimatetheresistanceoftheTICsif
their resistance is based on quiescence rather than expression
ofresistance-associatedproteinslikealdehydedehydrogenase
or ABC transporters. Additionally, what degree of change
in the IC50 that constitutes “chemoresistance” has not been
established.
2.1.5. Diﬀerentiation. A suspected TIC’s ability to diﬀeren-
tiate along a variety of lineages is considered an indicator
of pluripotency [12]. In sarcoma research, diﬀerentiation
into mesenchymal cell types such as osteoblasts, adipocytes,
and chondrocytes is typically evaluated, based on the theory
that a SIC is a mesenchymal stem cell that has undergone
malignant transformation. If, however, a SIC is a fully
diﬀerentiated cell that has acquired stem-like properties, it
may not be capable of transdiﬀerentiation to a diﬀerent
cell type. Furthermore, diﬀerentiating media may induce
diﬀerentiation in cancer cells regardless of their “stemness.”Sarcoma 3
2.2. Descriptive Assays
2.2.1. Expression of Stem Cell Genes. Expression of so-called
“ s t e mc e l lg e n e s ”s u c ha sO C T 4 ,S O X 2 ,a n dN A N O Gi sa l s o
used as a marker of TICs. These genes are transcription
factors found in embryonic stem cells and appear to be
necessary for maintenance of an undiﬀerentiated state,
pluripotency, and self-renewal [13]. However, there are
many such genes, and the number necessary to confer a
“stem cell” designation, as well as the level of expression
necessary, remains unclear. Moreover, these genes are often
expressednotonlyinstemcellsbutalsoincertaincommitted
progenitors, calling into question their speciﬁcity as “stem
cell genes.” Expression of these genes may simply be a
functionofthemalignanttransformationofthecellsandnot
unique to a TIC subpopulation.
2.2.2. Aldehyde Dehydrogenase Activity. Hematopoetic and
neural stem/progenitor cells have been shown to have high
activity of aldehyde dehydrogenase (ADLH) [14, 15]. It is
thus hypothesized that TICs would also have higher levels of
ALDH activity. ALDH “bright” or “high” cells are typically
isolated by incubating cells with a ﬂuorescent reagent (e.g.,
ALDEFLUOR), which is activated by ALDH. Flow cytometry
is then used to identify and compare the amount of ALDH
activity in a putative TIC population as compared to nonTIC
population.
3. Approaches to Stem Cell Isolation
3.1.CellSurfaceMarkers. Theﬁrstdeﬁnitiveworkdescribing
T I Cw a sp e r f o r m e di nA c u t eM y e l o i dL e u k e m i aw h e r et h e
surface marker phenotype CD34+, CD38− identiﬁes a small
subpopulation of cells that is able to propagate the leukemia,
while CD34+ cells that express CD38 cannot, despite having
the morphologic phenotype of leukemic blasts [16]. These
ﬁndings prompted other researchers to use surface markers
to identify TIC in other malignancies including breast, brain,
l u n g ,p r o s t a t e ,m e l a n o m a ,p a n c r e a s ,c o l o n ,l i v e r ,h e a da n d
neck, and ovarian cancers [17]. Several surface markers have
been studied in multiple malignancies as identiﬁers of TIC
including CD20, CD24, CD34, CD44, CD90, CD117, and
CD133 [17].
Of these, CD133 has garnered the most attention in
sarcomas. Originally described in 1997, CD133 is a 5-
t r a n s m e m b r a n ep r o t e i nw h o s ee x p r e s s i o nw a sr e s t r i c t e d
to CD34bright cells suggesting it was a viable marker of
hematopoetic stem and progenitor cells [18]. It was subse-
quently identiﬁed in epithelial cells and in endothelial and
neural progenitor cells. It was also used to identify potential
TIC in various cancers, including brain, colon, liver, lung,
ovarian, pancreatic, and prostate [17]. CD133’s function
and/or role in pluripotency remains unclear. CD133 appears
to be concentrated in plasma membrane protrusions such as
microvilli [19]. In addition, frameshift mutations of CD133
have been associated with retinal degeneration [20]. The
relevance of these ﬁndings to stem cell biology, however,
remains unclear.
The biological function of the surface markers used
to identify TIC, such as CD133, is often unclear. Though
our lack of understanding does not negate usefulness as a
cancer stem cell marker, furthering our knowledge about
these markers could help clarify their importance as markers
of stem cells and may lead to discovery of more accurate
markers (e.g., downstream targets). Furthermore, if a select
surface marker is simply a marker of cell viability, diﬀerences
between clonogenicity, sphere formation, tumorigenicity,
and so forth, may reﬂect a comparison between viable and
nonviable cells instead of stem cells and nonstem cells.
Interestingly, CD133 has been detected on the surface
of diﬀerentiated epithelial cells in a variety of tissues, and
at least one study has shown that CD133 expression is not
limited to tumor-initiating cells in colon cancer [33, 34]. In
addition, some studies have demonstrated tumor-initiating
activityincellsthatareCD133negative.Finally,otherstudies
have compared CD133 with other presumed markers of TIC.
Though the CD133+ cells still showed stem-like properties,
the CD133 cells are often outperformed in assays of cancer
stem cell function by cells identiﬁed by other techniques,
such as ALDH activity [35, 36].
3.2. ALDH. Aldehyde dehydrogenase (ALDH) is a detox-
ifying enzyme responsible for oxidation of intracellular
aldehydes [37]. It is found in many cells throughout the
body, but hematopoietic and neural stem/progenitor cells
have particularly high ADLH activity [38–40]. ALDH may
play a role in early diﬀerentiation of stem cells through
oxidizing retinol to retinoic acid and can confer resistance
to chemotherapeutic agents such as cyclophosphamide [41,
42]. High ALDH activity has been demonstrated in TIC
populations of breast, colon, and lung cancers among others
[1]. Just as high ALDH activity can be used as a measure of
“stemness,” isolation of the population with the highest level
of ALDH activity is thought to enrich for TICs. Typically,
cells with the highest ALDH activity, “ALDH-high”, are
compared to the subpopulation that shows the lowest ALDH
activity, “ALDH-low”, as well as cells that are simply passed
through the ﬂow cytometer without ALDH selection, “ﬂow
through”.
One of the biggest challenges of using ALDH as a marker
of TIC is the arbitrary nature of the 2 or 3% cut-oﬀ of
cellswiththehighestandlowestALDHactivity.Additionally,
ALDH is a marker of cell viability or detoxifying ability, so
perhaps the enhanced ability of ALDH-high cells to grow
colonies, spheres, or in vivo tumors may simply reﬂect a
healthier cell population.
3.3. Side Population. Goodell et al. noted a distinct popula-
tion of murine bone marrow cells that stained poorly with
the Hoechst 33342 dye [43]. Cells within this population,
termed the “side population” (SP) due to its position in
the ﬂow cytometry plot, were found to have many of
the characteristics of hematopoetic stem cells. This group
determined that the reason for the low Hoechst staining was
eﬄux of the dye mediated by ATP-binding cassette (ABC)
transporterproteins.Chemotherapydrugsarealsosubstrates4 Sarcoma
for these eﬄux pumps, suggesting a mechanism for drug
resistance in these cells. SPs have since been used to identify
both normal stem cell and TIC populations. Several groups
have used SP as a sign of “stemness” to support the idea that
the marker they were studying identiﬁed stem cells; however,
identifyingaputativecancerstemcellpopulationbyisolating
the SP has a few shortcomings including inherent toxicity of
the dye giving cells that eﬄux it a survival advantage and
that stem cells have been isolated from the nonSP as well,
suggesting that dye eﬄux is not an essential characteristic of
stem cells [17–19].
4. Evidence for TIC in Sarcomas
The assays discussed above have been applied to numerous
sarcoma subtypes (Table 2). This work has been variably
s u c c e s s f u la n di ss u m m a r i z e db e l o w .
4.1. Osteosarcoma. Tirino et al. isolated a CD133+ subpopu-
lation in osteosarcoma cell lines SAOS2, MG63, and U2OS
that demonstrated increased stem-like properties as com-
pared to the CD133− population [21]. Their experiments
included sphere formation, growth in soft agar, expression
of the stem cell gene OCT3/4, presence of a side-population
as evidenced by Hoechst dye exclusion, and growth and
proliferation assays. Subsequent ﬂow cytometric analysis of
21 human primary sarcomas and 2 osteosarcoma cell lines
derived from biopsies again demonstrated that CD133+ cells
exhibit stem cell-like properties [22].
Adhikari et al. investigated a population that was CD117
and Stro-1 double-positive as a potential cancer stem cell
in osteosarcoma [23]. CD117, also known as c-KIT, is a
protooncogene that is expressed on many hematopoietic
progenitor cells. Stro-1 is believed to be a marker of
osteogenic progenitor cells in bone marrow. Both murine
and human osteosarcoma cells were plated in a sphere-
forming assay, and the cells from the spheres were then
analyzed for expression of stem cell markers compared to
the same cell lines growing in a monolayer. CD117, Stro-1,
and the ABC transporter ABCG2 were expressed at higher
levels in the sphere cells. The sphere cells from mouse
osteosarcoma cell lines were more tumorigenic, with 2 of 5
and 2 of 4 mice growing tumors with as few as 200 cells
isolated from spheres injected. Double-positive (DP) cells
(CD117+andStro-1+)from3mouseosteosarcomacelllines
were also more tumorigenic with 7 of 7 and 4 of 6 mice
growing tumor when injected with 200 DP cells with two
of the cell lines and 3 of 5 mice growing tumor with 2,000
DP cells injected from a third mouse osteosarcoma cell line.
None of the mice injected with comparable double-negative
(DN) cells from either cell line grew tumor. Comparing DP
toDNcellsfromthreehumanosteosarcomacelllinesshowed
7 of 8 versus 1 of 8 mice growing tumor when injected with
equal number of DP or DN cells, respectively, in two of the
cell lines, while the third cell line showed that 3 of 4 mice
injectedwithDPcellsgrewtumorcomparedto0of4injected
with the same number of DN cells from the same human
osteosarcoma cell line. Finally, comparison between DP and
DN cells from two of the mouse osteosarcoma cell lines
showed a shift in IC50 and increased cell survival percentage
in the DP cells when treated with doxorubicin.
Wang et al. demonstrated a subpopulation with high
ALDH activity in the osteosarcoma cell line OS99-1 [24].
They were able to grow xenografts in NOD/SCID mice
with this cell line, and the cells with high ALDH activity
isolated from the xenografts showed greater tumorgenicity,
generatingnewtumorswithasfewas100cells.TheseALDH-
high cells showed characteristic cancer stem cell features
of self-renewal, ability to produce diﬀerentiated progeny,
and increased expression of the stem cell genes OCT3/4A,
NANOG, and SOX-2.
Murase et al. used the approach of sorting with Hoechst
dye to study 7 osteosarcoma cell lines (NY, OS2000, KIKU,
Huo9, HOS, Saos2 and U2OS) and 1 bone malignant
ﬁbrous histiocytosis cell line (MFH2003) [25]. Of these, only
the NY osteosarcoma cell line and the MFH2003 cell line
showed a signiﬁcant SP. Further testing of the MFH2003
cell line showed increased sphere-forming activity and soft
agar colony formation in the SP cells. Implantation of serial
dilutions of SP and nonSP cells into immunodeﬁcient mice
showedthat1of5miceinjectedwith103 SPcellsgrewtumor,
while tumor growth was not seen in nonSP cells when fewer
than 105 cells were injected.
4.2. Ewing’s Sarcoma. Suv` a et al. used CD133 to identify
a subpopulation of Ewing’s sarcoma cells that demonstrate
tumor-initiating activity and sustained growth through
serial xenotransplantations, reestablishing after every in vivo
passage a cellular hierarchy of TICs (CD133+) and progeny
(CD133−)[ 26]. Additionally, they found CD133+ Ewing’s
sarcoma cells capable of diﬀerentiation to adipogenic,
osteogenic, and chondrogenic lineages. The CD133 cells
also expressed signiﬁcantly higher levels of the stem cell
genes OCT4, SOX2, and NANOG. This same group later
expressed the fusion gene, EWS-FLI1, which characterizes
most Ewing’s sarcomas, in pediatric mesenchymal stem
cells, and demonstrated that it induced a transcriptome
similar to that of Ewing’s sarcoma family tumors [27]. These
transformed cells also appeared to have a subpopulation that
expressed CD133, the stem cell genes OCT4, SOX2, and
NANOG, and in vitro sphere-forming ability. Prompted in
part by these ﬁndings, Jiang et al. investigated the expression
of CD133 in primary Ewing’s tumors and cell lines to see
if there was a correlation between CD133 expression and
chemoresistance [28]. Of the 48 sources tested, most had
very low or absent expression of the CD133− encoding
gene PROM1 while 4 cases had overexpression of PROM1.
Of these 4, 2 were found to have quickly developed a
chemoresistant tumor while the other 2 were long-term
survivors after receiving chemotherapy. These results suggest
heterogeneity of CD133 expression in Ewing’s sarcomas and
a variable prognostic impact of the level of expression.
Awad et al. tested ALDH activity in Ewing’s sarcoma
[35]. Five Ewing’s sarcoma cell lines were treated with
ALDEFLUOR, and the 2% of cells with the highest ALDH
activity (ALDH-high) were isolated as were the 2% of
cells with the lowest ALDH activity (ALDH-low). UnsortedSarcoma 5
Table 2: Studies showing isolation of sarcoma-initiating cells.
Tumor Type Technique Summary of ﬁndings Reference
Osteosarcoma
CD133+ cells demonstrated increased sphere formation, growth in
soft agar, expression of OCT3/4, and presence of side population CD133 [21, 22]
Double positive (CD117+ and Stro-1+) cells were seen with a
higher incidence in spheres, and they showed higher
tumorigenicity as well as chemoresistance
CD117, Stro-1 [23]
ALDH-high cells isolated from xenografts established from cell
line OS99-1 had increased tumorigenicity, self-renewal, and ability
to produce diﬀerentiated progeny, and expressed increased levels
of OCT3/4A, NANOG, and SOX-2
ALDH [24]
SP was seen in 1 of 7 osteosarcoma cell lines tested. SP population
had increased sphere- and colony-forming activity and increased
tumorigenicity
SP [25]
Ewing’s sarcoma
CD133+ cells showed increased tumorigenicity, ability to establish
a heterogeneous population and diﬀerentiation, and increased
expression of OCT4, SOX2, and NANOG. There was a correlation
in primary tumors between higher expression of CD133 and
chemoresistance
CD133 [26–28]
ALDH-high cells showed increased sphere- and colony-forming
ability, chemoresistance, SP, and tumorigenicity ALDH [35]
Rhabdomyosarcoma
Serial passages of rhabdomyosarcoma spheres enriched for cells
with increased expression of OCT4, NANOG, c-Myc, SOX2, and
PAX3 and increased expression of CD133 and CD133+cells
showed increased tumorigenicity, ability to Diﬀerentiate, and
chemoresistance. CD133 expression also correlated with poorer
survival in patient samples
CD133 [30]
Synovial sarcoma 5 of 5 primary tumor samples and 3 of 3 cell lines demonstrate a
CD133+ subpopulation, but not TIC properties were tested CD133 [31]
Multiple sarcomas
Size of SP in primary tumor samples correlated with tumor grade.
SP cells from 1 osteosarcoma, 1 synovial sarcoma, and 2 malignant
ﬁbrous histiocytosis samples showed increased tumorigenicity and
ability to produce a heterogeneous cell population (SP and nonSP)
SP [32]
“ﬂowthrough” cells were also collected as controls. The
ALDH-high population in all ﬁve cell lines showed increased
clonogenicity, sphere-forming ability, and 4 of the 5 cell
lines showed ALDH-high cells to be more resistant to
doxorubicin than ALDH-low and ﬂowthrough cells. The
ﬁfth cell line, A4573, is known to be inherently resistant
to doxorubicin [29]. Chemoresistance was hypothesized
to be due to higher expression of ATP-binding cassette
(ABC) transporter proteins causing drug eﬄux. There was
signiﬁcantly increased Hoechst dye eﬄux seen in ALDH-
high cells as compared to ALDH-low cells. The ALDH-high
cells were also able to produce a heterogeneous population
of both ALDH-high and ALDH-low cells, while ALDH-low
cells only produced ALDH-low progeny. ALDH-high cells
expressed signiﬁcantly higher levels of the stem cell genes
OCT4, BMI-1, and NANOG. Finally, in vivo experiments
were performed with two of the cell lines, TC71 and MHH.
Asfewas160ALDH-highcellswereabletogenerateaserially
transplantable tumor in NOD/SCID/IL-2Rγ null mice, while
no tumor growth was seen with 80,000 or less ALDH-low
cells,and3of7miceinjectedwith80,000unsortedcellsgrew
tumor, but none grew tumor with less than 80,000 unsorted
cells injected. Immunohistochemistry showed ∼1% of cells
in xenografted tumors staining intensely for ALDH, includ-
ing the tumors that grew from ALDH-high cell injection,
suggesting the ability to generate heterogeneous progeny.6 Sarcoma
Finally, 22 primary biopsy specimens from patients with
Ewing’s sarcoma were tested with immunohistochemistry
and demonstrated a spectrum of ALDH expression with a
small minority of the cells exhibiting very intense staining
for ALDH.
4.3. Rhabdomyosarcoma. Walter et al. explored TICs in
embryonal rhabdomyosarcoma [30]. They used serial pas-
sages of rhabdomyosarcoma spheres to enrich for TICs and
foundupregulationofthestemcellgenesOCT4,NANOG,c-
Myc, SOX2, and PAX3. These enriched rhabdomyosarcoma
spheres also demonstrated a 100-fold increase in tumori-
genicity, causing tumor formation in xenografts with 104
enriched sphere cells compared to 106 of the nonenriched
cells. CD133 gene and protein expression was found to be
upregulated in the rhabdomyosarcoma sphere population
as compared to adherent rhabdomyosarcoma cells. CD133+
and CD133− rhabdomyosarcoma cells were isolated and
injected into immunodeﬁcient NOD/SCID mice and the
CD133+ cells showed tumor growth at lower numbers of
injected cells, 102 versus 106, although only 1 mouse out
of each cohort of 4 grew tumor at the lower dilutions
of CD133+ cells, 102 and 103. The CD133+ cells showed
adipogenic, osteogenic, and chondrogenic diﬀerentiation
potential. CD133+ cells were also chemoresistant compared
to CD133− cells, with signiﬁcantly increased colony forma-
tion in agar after treatment with cisplatin and chlorambucil.
Finally,76patientsamplesofembryonalrhabdomyosarcoma
were stained for CD133. Patients whose tumor expressed a
low or intermediate level of CD133 had an overall survival
rate of 75%, while patients with high CD133-expressing
tumors had a signiﬁcantly lower overall survival rate of 50%.
4.4. Nonrhabdomyosarcoma Soft Tissue Sarcoma. Terry and
Nielsen have shown subpopulations of CD133-expressing
cells in 5 of 5 primary synovial sarcomas and 3 of 3 synovial
sarcomacelllines[31].However,todate,TICpropertieswere
not assessed in these CD133+ cell compared to the rest of the
tumor cells.
Wu et al. examined 29 primary human tumors of mes-
enchymal origin including 7 aggressive ﬁbromatosis, 5
osteosarcomas, 3 chondrosarcomas, 3 synovial sarcomas,
2 leiomyosarcoma, 4 malignant ﬁbrous histiocytomas, 1
myxoid liposarcoma, 1 pleomorphic liposarcoma, 1 der-
matoﬁbrosarcoma protuberans, 1 myxoid chondrosarcoma,
and 1 chordoma [32]. They identiﬁed a SP in all but 6 of
the tumors tested, the dermatoﬁbrosarcoma protuberans,
the myxoid chondrosarcoma, 1 of the chondrosarcomas, 1
malignant ﬁbrous histiocytoma, 1 leiomyosarcoma, and a
synovial sarcoma. They observed a correlation between the
size of the SP and tumor grade. SP and nonSP cells from
one osteosarcoma, one synovial sarcoma, and 2 malignant
ﬁbrous histiocytosis samples were injected into NOD/SCID
mice. The SP cells generated tumors at a higher frequency
and with fewer injected cells than the nonSP cells. The SP-
generated tumors were also signiﬁcantly larger and heavier
and were more readily transplantable. Finally, only tumors
derived from the SP cells were able to repopulate both the
SP and nonSP fractions when stained with Hoechst dye and
resorted.
5. Conclusions
Identiﬁcation of SICs is fraught with diﬃculties. Underlying
many of the challenges in this ﬁeld is the lack of accepted
means by which to isolate normal mesenchymal stem
cells. This issue clouds the ongoing debate about whether
SICs reﬂect mesenchymal stem cells “gone bad” or if they
arise from diﬀerentiated cells that have acquired stem-
like properties as a result of the tumorigenic mutations
[11]. The mesenchymal origin of some sarcomas even
remains controversial, with some support, for example, for
a neuroectodermal origin for these tumors [44]. Finally,
sarcoma research struggles with the heterogeneity of the
malignancies lumped under the term “sarcomas.” What
holds true for an osteosarcoma may not be valid for a
pleomorphic undiﬀerentiated sarcoma.
Despite years of study, SIC research remains a ﬂedgling
ﬁeld, building in large part on the ﬁndings from more
common cancers such as breast, colon, and hematopoetic
malignancies. Sheer numbers enable research in those can-
cers to progress more rapidly. Extrapolation from epithelial
malignancies, though, may be misleading. One of the major
concepts in the study of carcinoma TICs is the link between
a stem-like phenotype and epithelial-to-mesenchymal tran-
sition (EMT). It is not clear how relevant EMT is to the
development of SICs, which already have a mesenchymal
phenotype.
The methods employed to identify SICs share one
important ﬂaw: they are not able to isolate a pure TIC
population. Each technique only selects for a population
that is enriched for cells with stem-like properties. One
could envision a Venn diagram of all the markers listed, and
perhaps additional ones as they emerge, where the intersec-
tion of all markers would identify a pure SIC population.
Some groups have evaluated the combination of CD133 and
ALDH, for example, as a means of further purifying a TIC
population in a variety of malignancies [45–48]. There are,
however, many competing studies touting the superiority
of one marker over another and few showing any additive
or complementary eﬀect of combining multiple markers,
especially in sarcomas [44, 45]. Furthermore, whether the
cells responsible for refractoriness to chemotherapy and
those responsible for metastases are one, and the same
has been called into question [1, 49]. It may be that one
of the techniques for identifying TICs is more suited for
identifying cells with metastatic potential while another
technique identiﬁes chemoresistant cells. Finally, Chaﬀer et
al. have recently raised an additional confounding concept:
a cancer cell might be able to convert to and from a stem-
like state [50]. If “stemness” is a state that cells can adopt in
response to environmental cues, for example, isolation of a
pure TIC population may not be possible.
The existence of TICs in sarcomas is an enticing propo-
sition; it would explain in part why our success in treating
these tumors has been limited. In addition, the existenceSarcoma 7
of SICs would give us a target for new therapies that
would complement existing treatments. Perhaps the means
to identify these cells lies within the techniques and markers
described above, or perhaps the next proposed marker will
be the key. For this, we may have to continue to look towards
the advances our colleagues are making in studying more
common tumors. We must, however, also be judicious in
adopting strategies that may not apply to our ﬁeld. The
identiﬁcation of SICs would be greatly aided by a better
understanding of the origin of sarcomas and TICs in general
and establishment of clear criteria for the testing of proposed
TIC subpopulations. If what we are looking for is not clearly
deﬁned, we will never ﬁnd it.
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